Compare AGPU & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | MBRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.1M |
| IPO Year | N/A | 2016 |
| Metric | AGPU | MBRX |
|---|---|---|
| Price | $3.94 | $2.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 4.9M | 86.4K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12,476.23 | N/A |
| Revenue Next Year | $55.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.25 |
| 52 Week High | $9.00 | $7.98 |
| Indicator | AGPU | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 56.73 |
| Support Level | $1.14 | $0.39 |
| Resistance Level | $8.72 | $5.15 |
| Average True Range (ATR) | 0.90 | 0.14 |
| MACD | 0.33 | 0.09 |
| Stochastic Oscillator | 54.88 | 96.07 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.